FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984082201> ?p ?o ?g. }

• W2984082201 endingPage "361" @default.
• W2984082201 startingPage "351" @default.
• W2984082201 abstract "Background: With 1.3 million new cases in 2018 worldwide, prostate cancer remains a challenge. Development of novel therapies targeting the androgen pathway followed recognition of the continued importance of androgens in castrate-resistant prostate cancer. To assess abiraterone and enzalutamide efficacy we analyzed data from US Veterans Administration Medical Centers (VAMCs). Methods: We used a novel method independent of assessment intervals and ideal for real-world analysis to estimate rates of tumor growth (g) and regression (d). Findings: Using the VA Informatics and Computing Infrastructure, we collected data from 5,116 Veterans with castrate-resistant prostate cancer prescribed abiraterone, enzalutamide or both. We estimated values for g and d and demonstrated a correlation of g with overall survival (P < .0001). Abiraterone and enzalutamide slowed growth rates across age groups and across the entire VAMC system, although less so in Veterans previously treated with a taxane and those with Gleason grade group 5 tumors. Abiraterone and enzalutamide efficacy in first-line were comparable although abiraterone in first-line slowed growth rates significantly more in African Americans than in Caucasians; enzalutamide was a better salvage therapy. When abiraterone was first-line and g was low, switching to enzalutamide was associated with a faster g in 67%. Interpretation: In the real-world g can be estimated using a novel analysis method indifferent to assessment intervals that correlates highly with OS. While we show excellent real-world outcomes with abiraterone and enzalutamide, 2 effective and tolerable therapies, our results in VAMCs suggest enzalutamide should follow abiraterone. Changing therapies may be detrimental and consideration should be given to continue monitoring of growth rates over time. Funding Support from the Prostate Cancer Foundation and the Blavatnik Family Foundation." @default.
• W2984082201 created "2019-11-22" @default.
• W2984082201 creator A5002168058 @default.
• W2984082201 creator A5006092876 @default.
• W2984082201 creator A5013592290 @default.
• W2984082201 creator A5016528073 @default.
• W2984082201 creator A5031310463 @default.
• W2984082201 creator A5041547707 @default.
• W2984082201 creator A5046416890 @default.
• W2984082201 creator A5047563476 @default.
• W2984082201 creator A5049808872 @default.
• W2984082201 creator A5051429711 @default.
• W2984082201 creator A5056816160 @default.
• W2984082201 creator A5064301200 @default.
• W2984082201 creator A5067522153 @default.
• W2984082201 creator A5077305663 @default.
• W2984082201 date "2019-08-01" @default.
• W2984082201 modified "2023-10-16" @default.
• W2984082201 title "A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide" @default.
• W2984082201 cites W1966938766 @default.
• W2984082201 cites W1973808708 @default.
• W2984082201 cites W2055346449 @default.
• W2984082201 cites W2110534364 @default.
• W2984082201 cites W2113499049 @default.
• W2984082201 cites W2121023961 @default.
• W2984082201 cites W2134421056 @default.
• W2984082201 cites W2135636495 @default.
• W2984082201 cites W2137467802 @default.
• W2984082201 cites W2148643283 @default.
• W2984082201 cites W2162383970 @default.
• W2984082201 cites W2166918329 @default.
• W2984082201 cites W2168167318 @default.
• W2984082201 cites W2560688864 @default.
• W2984082201 cites W2563153623 @default.
• W2984082201 cites W2589905837 @default.
• W2984082201 cites W2620746860 @default.
• W2984082201 cites W2620798309 @default.
• W2984082201 cites W2746053356 @default.
• W2984082201 cites W2792086148 @default.
• W2984082201 cites W2810806599 @default.
• W2984082201 cites W2884762657 @default.
• W2984082201 cites W2891141194 @default.
• W2984082201 cites W2911188335 @default.
• W2984082201 doi "https://doi.org/10.1053/j.seminoncol.2019.11.004" @default.
• W2984082201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31757478" @default.
• W2984082201 hasPublicationYear "2019" @default.
• W2984082201 type Work @default.
• W2984082201 sameAs 2984082201 @default.
• W2984082201 citedByCount "12" @default.
• W2984082201 countsByYear W29840822012019 @default.
• W2984082201 countsByYear W29840822012020 @default.
• W2984082201 countsByYear W29840822012021 @default.
• W2984082201 countsByYear W29840822012022 @default.
• W2984082201 countsByYear W29840822012023 @default.
• W2984082201 crossrefType "journal-article" @default.
• W2984082201 hasAuthorship W2984082201A5002168058 @default.
• W2984082201 hasAuthorship W2984082201A5006092876 @default.
• W2984082201 hasAuthorship W2984082201A5013592290 @default.
• W2984082201 hasAuthorship W2984082201A5016528073 @default.
• W2984082201 hasAuthorship W2984082201A5031310463 @default.
• W2984082201 hasAuthorship W2984082201A5041547707 @default.
• W2984082201 hasAuthorship W2984082201A5046416890 @default.
• W2984082201 hasAuthorship W2984082201A5047563476 @default.
• W2984082201 hasAuthorship W2984082201A5049808872 @default.
• W2984082201 hasAuthorship W2984082201A5051429711 @default.
• W2984082201 hasAuthorship W2984082201A5056816160 @default.
• W2984082201 hasAuthorship W2984082201A5064301200 @default.
• W2984082201 hasAuthorship W2984082201A5067522153 @default.
• W2984082201 hasAuthorship W2984082201A5077305663 @default.
• W2984082201 hasConcept C121608353 @default.
• W2984082201 hasConcept C126322002 @default.
• W2984082201 hasConcept C126894567 @default.
• W2984082201 hasConcept C143998085 @default.
• W2984082201 hasConcept C2776421732 @default.
• W2984082201 hasConcept C2776551883 @default.
• W2984082201 hasConcept C2780192828 @default.
• W2984082201 hasConcept C2781190966 @default.
• W2984082201 hasConcept C61367390 @default.
• W2984082201 hasConcept C71924100 @default.
• W2984082201 hasConceptScore W2984082201C121608353 @default.
• W2984082201 hasConceptScore W2984082201C126322002 @default.
• W2984082201 hasConceptScore W2984082201C126894567 @default.
• W2984082201 hasConceptScore W2984082201C143998085 @default.
• W2984082201 hasConceptScore W2984082201C2776421732 @default.
• W2984082201 hasConceptScore W2984082201C2776551883 @default.
• W2984082201 hasConceptScore W2984082201C2780192828 @default.
• W2984082201 hasConceptScore W2984082201C2781190966 @default.
• W2984082201 hasConceptScore W2984082201C61367390 @default.
• W2984082201 hasConceptScore W2984082201C71924100 @default.
• W2984082201 hasFunder F4320309346 @default.
• W2984082201 hasFunder F4320312914 @default.
• W2984082201 hasIssue "4-5" @default.
• W2984082201 hasLocation W29840822011 @default.
• W2984082201 hasOpenAccess W2984082201 @default.
• W2984082201 hasPrimaryLocation W29840822011 @default.
• W2984082201 hasRelatedWork W122177069 @default.
• W2984082201 hasRelatedWork W1512914561 @default.
• W2984082201 hasRelatedWork W1652439388 @default.

• next